Cargando…

A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma

LESSONS LEARNED. Oral targeted agents are desirable for treatment of Kaposi sarcoma (KS); however, in patients with HIV, drug–drug interactions must be considered. In this study to treat KS, sorafenib was poorly tolerated at doses less than those approved by the U.S. Food and Drug Administration for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uldrick, Thomas S., Gonçalves, Priscila H., Wyvill, Kathleen M., Peer, Cody J., Bernstein, Wendy, Aleman, Karen, Polizzotto, Mark N., Venzon, David, Steinberg, Seth M., Marshall, Vickie, Whitby, Denise, Little, Richard F., Wright, John J., Rudek, Michelle A., Figg, William D., Yarchoan, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2017
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423501/ https://www.ncbi.nlm.nih.gov/pubmed/28341759 http://dx.doi.org/10.1634/theoncologist.2016-0486

Ejemplares similares

Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are associated with markedly elevated serum IL-10, elevated IL-6, IL-17 and circulating KSHV
por: Uldrick, Thomas S, et al.
Publicado: (2012)

Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi sarcoma-associated herpes virus (KSHV) associated multicentric Castleman disease (MCD)
por: Uldrick, Thomas, et al.
Publicado: (2010)

[(18)F]-fluoro-D-deoxyglucose positron emission tomography findings in Kaposi sarcoma herpes virus associated multicentric Castleman disease: correlation with clinical, inflammatory, and virologic parameters
por: Polizzotto, Mark N, et al.
Publicado: (2012)

Polymorphisms in KSHV-encoded microRNA sequences affect levels of mature viral microRNA in Kaposi Sarcoma lesions
por: Marshall, Vickie A., et al.
Publicado: (2018)

Evaluation of Non-Invasive Multispectral Imaging as a Tool for Measuring the Effect of Systemic Therapy in Kaposi Sarcoma
por: Kainerstorfer, Jana M., et al.
Publicado: (2013)

Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV–MCD) and the KSHV Inflammatory Cytokine Syndrome
por: Polizzotto, Mark N., et al.
Publicado: (2012)

Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome
por: Polizzotto, Mark N., et al.
Publicado: (2017)

KSHV activation, human and viral IL-6 production, and other cytokine dysregulation: Association with the symptomatology of KSHV-associated multicentric Castleman’s disease
por: Polizzotto, Mark N, et al.
Publicado: (2010)

Signatures of oral microbiome in HIV-infected individuals with oral Kaposi's sarcoma and cell-associated KSHV DNA
por: Gruffaz, Marion, et al.
Publicado: (2020)

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
por: Srkalovic, Gordan, et al.
Publicado: (2014)

Heterogeneity and Breadth of Host Antibody Response to KSHV Infection Demonstrated by Systematic Analysis of the KSHV Proteome
por: Labo, Nazzarena, et al.
Publicado: (2014)

Interim results of a clinical trial using oncolytic virotherapy in Kaposi's sarcoma-associated herpesvirus (KSHV) associated-Multicentric Castleman's Disease (MCD)
por: Yarchoan, R, et al.
Publicado: (2009)

Genetic variation in KSHV encoded microRNAs affects microRNA expression and is associated with multicentric Castleman’s disease risk
por: Marshall, Vickie, et al.
Publicado: (2012)

A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2018)

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
por: Greenwald, Daniel R, et al.
Publicado: (2013)

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
por: Molhoek, Kerrington R, et al.
Publicado: (2005)

Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Shahda, Safi, et al.
Publicado: (2016)

Kaposi sarcoma herpesvirus viral load as a biomarker for leptomeningeal involvement by primary effusion lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2022)

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
por: Awada, A, et al.
Publicado: (2005)

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
por: Grierson, Patrick M, et al.
Publicado: (2022)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma
por: Burbelo, Peter D, et al.
Publicado: (2010)

A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma
por: Zhang, Yang, et al.
Publicado: (2022)

Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
por: Patt, Yehuda, et al.
Publicado: (2017)

Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2017)

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022)

Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)
por: Ostwal, Vikas, et al.
Publicado: (2022)

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors
por: Beatty, Gregory L., et al.
Publicado: (2018)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

Sorafenib for Patients with Hepatocellular Carcinoma and Child‐Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study
por: Labeur, Tim A., et al.
Publicado: (2019)

Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label, Phase Ib Study
por: Lin, Chia‐Chi, et al.
Publicado: (2020)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)
por: Suh, Koung Jin, et al.
Publicado: (2023)

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
por: Lieu, Christopher H., et al.
Publicado: (2017)

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
por: Ko, Andrew H, et al.
Publicado: (2023)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
por: Johnson, Melissa L, et al.
Publicado: (2023)

T-cell responses to KSHV infection: a systematic approach
por: Roshan, Romin, et al.
Publicado: (2017)

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
por: Carlo, Maria I., et al.
Publicado: (2016)

Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study
por: Haigentz, Missak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ln3lp0j0rcdn77of6cpoj64dhv